ABSTRACT

Nowadays, cancer immunotherapy is a cutting-edge malignancy treatment. Immunotherapy has been shown to offer unmatched benefits over conventional anti-tumor therapy in several experimental and clinical studies, which can increase both progression-free survival (PFS) and overall survival (OS). On the other hand, immunotherapy is unclear and complex. A hyperactive immune system might potentially result in serious side effects from immunotherapy. Immunological checkpoints that are more efficient and have fewer side effects are constantly being investigated. By weighing the benefits and drawbacks of immunotherapy and closely monitoring its future development trend, this review provides an overview of current advancements in the field. It suggests a new approach to tumor treatment. In terms of survival rates and overall quality of life, cancer immunotherapy has led to substantial advancements in patient outcomes compared to traditional treatments like chemotherapy, radiation, and surgery. It has become a key component of modern cancer care, with applications ranging from early-stage (adjuvant and neo adjuvant) settings to advanced metastatic disease across various cancer types. Keywords: Cancer immunotherapy, Immune checkpoint blockade therapies, natural killer (NK) cells, ACI (adoptive cellular Immunotherapy) TGR (tumor growth rate)
Publication date: 01/06/2026

https://www.ijbpas.com/pdf/2026/June/MS_IJBPAS_2026_10259.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2026/15.6.10259